NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/06/2026
Voltar para busca
Dado oficial do USPTO
BELESALA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
35
Atualização mais recente
05/06/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 10
Data de depósito
10/09/2019
Data de registro
27/10/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
27/10/2020
Última transação
05/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
77
Localização do titular
IE
Examinador
JAGANNATHAN, SIDDHARTH
Unidade examinadora
M50
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Mallinckrodt Pharmaceuticals Ireland Limited
Representantes
Camille M. Miller Cozen O'Connor
Classificação técnica
Classes Nice
Classe 5Classe 10
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for the treatment of neurological diseases and disordersnephrotic diseasesendocrine disordersrheumatic disorderscollagen diseasesdermatologic diseases and disordersallergic statesophthalmic diseasesrespiratory diseaseshematologic disordersneoplastic diseasesedematous stategastrointestinal diseaseshepatic diseases and disordersbiliary diseases and disordersrenal disorderscardiovascular and lipid-related diseases and disordersinflammatory and autoimmune diseases and disorders; intravenous analgesics and antipyretics; syringes sold prefilled with pharmaceutical preparations for the treatment of neurological diseases and disordersnephrotic diseasesendocrine disordersrheumatic disorderscollagen diseasesdermatologic diseases and disordersallergic statesophthalmic diseasesrespiratory diseaseshematologic disordersneoplastic diseasesedematous stategastrointestinal diseaseshepatic diseases and disordersbiliary diseases and disordersrenal disorderscardiovascular and lipid-related diseases and disordersinflammatory and autoimmune diseases and disordersintravenous analgesics and antipyretics
Classe 10
Medical apparatus and instruments for use in connection with the administration of gases to patients for medical and therapeutic purposes and accessories and parts thereofmedical and therapeutic gas delivery systems comprised primarily of gas cylindersvalvesregulatorsflow metersdelivery hoses and apparatus and instruments for settingmeasuring and regulating the mixture of medical and therapeutic gases delivered to patients; therapeutic medical device and accessories and parts thereof for extracting blood from the bodyseparating bloodtreating it extracorporallyreturning it to the body used for extracorporeal photopheresisextracorporeal photo immune therapyextracorporeal photo chemotherapycellular therapies; medical devicemedical syringes used for manual injection
Publicações
Histórico de despachos e eventos da marca no USPTO.
35 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
13/03/2026
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
13/03/2026
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
13/03/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
13/03/2026
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
27/10/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
21/01/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/04/2021
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
11/02/2021
XXCR
GENERIC MADRID TRANSACTION CREATED
11/02/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
27/01/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
27/10/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/08/2020
PUBO
PUBLISHED FOR OPPOSITION
11/08/2020
GPNX
NOTIFICATION PROCESSED BY IB
07/08/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
22/07/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
22/07/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
22/07/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/07/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
07/07/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
07/07/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
07/07/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
07/07/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/07/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/07/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/07/2020
RFNT
REFUSAL PROCESSED BY IB
08/02/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
21/01/2020
RFRR
REFUSAL PROCESSED BY MPU
21/01/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/12/2019
CNRT
NON-FINAL ACTION WRITTEN
11/12/2019
DOCK
ASSIGNED TO EXAMINER
11/12/2019
MAFR
APPLICATION FILING RECEIPT MAILED
10/12/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/12/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
05/12/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BELESALA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.